Welcome to the Future of Epigenetic Research
At Epigenica, we build innovative products for epigenetic analysis that foster scientific breakthroughs to advance human health.
Barriers to Epigenetic Research
Current commercial epigenomics technologies are limited by their ability to profile one or a few marks and samples at a time, at low throughput and high cost. Today, researchers can screen for either DNA methylation (DNAm) or histone post-translational modifications (HPTMs) – but not both simultaneously. Experiments also require many cells to generate accurate information. Considerable input material is needed to undertake comprehensive, epigenetic screens across multiple samples and multiple epigenetic markers, because it’s difficult to make quantitative comparisons across studies or samples, the utility of epigenetic research is limited.
Our EpiFinder™ platform is a first-in-class multiplexed ChIP-seq technology for high-throughput analysis of epigenetic marks that lets scientists explore epigenetic biomarkers with unprecedented speed, scalability, and affordability. Powered by our patented hmqChIP-seq technology, the EpiFinder™ platform overcomes barriers to epigenetics research with:
- High multiplexing
- High throughput
- Quantitative epigenomic maps
- Ability to combine DNAm and HPTM for a streamlined workflow
- Low amounts of input material
- Optimized to work with an array of starting materials
The EpiFinder™ GenomePro Kit
The First Commercial High-throughput and Multiplex ChIP-seq Kit for Epigenetics
Generating 192 quantitative genome-wide profiles – equivalent to running 192 parallel ChIP-seq experiments, in a fraction of the time – , EpiFinder™ GenomePro brings in-depth insights for biomedical research, drug discovery and development, and precision medicine.